Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University.
Department of Pathology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University.
Environ Health Prev Med. 2022;27:3. doi: 10.1265/ehpm.21-00254.
SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 2) is an important ATPase catalytic subunit in the switch-sucrose nonfermenting (SWI/SNF) complex. However, its relationship with the pathological features of NSCLC and its prognosis remain unclear.
We retrospectively reviewed 2390 patients with surgically resected NSCLC, constructed tissue microarrays (TMAs) and performed immunohistochemical assays. We analyzed the correlation of SAMRCA2 with clinicopathological features and evaluated its prognostic value.
Among 2390 NSCLC cases, the negative expression ratios of SAMRCA2, SMARCA4, ARID1A, ARID1B and INI1 were 9.3%, 1.8%, 1.2%, 0.4% and 0%, respectively. In NSCLC, male sex, T3 and T4 stage, moderate and poor differentiation, tumor ≥ 2 cm, Ki67 ≥ 15%, SOX-2 negative expression, middle lobe lesion and adenocarcinoma were relative risk factors affecting SMARCA2-negative expression. In lung adenocarcinomas, high-grade nuclei, histological morphology of acinar and papillary, solid and micropapillary and TTF-1-negative expression were relative risk factors affecting SMARCA2-negative expression. Kaplan-Meier survival analysis showed that the OS was shorter in the SMARCA2-negative group. Multivariate survival analysis revealed that SMARCA2-negative expression was an independent factor correlated with a poor prognosis in NSCLC.
In conclusion, SMARCA2-negative expression is an independent predictor of a poor outcome of NSCLC and is a potential target for NSCLC treatment.
SMARCA2（SWI/SNF 相关，基质相关，肌动蛋白依赖性染色质调节剂，亚家族 A，成员 2）是开关蔗糖非发酵（SWI/SNF）复合物中的重要 ATP 酶催化亚基。然而，其与非小细胞肺癌（NSCLC）的病理特征及其预后的关系尚不清楚。
我们回顾性分析了 2390 例接受手术切除的 NSCLC 患者，构建了组织微阵列（TMA）并进行了免疫组织化学检测。我们分析了 SMARCA2 与临床病理特征的相关性，并评估了其预后价值。
在 2390 例 NSCLC 病例中，SMARCA2、SMARCA4、ARID1A、ARID1B 和 INI1 的阴性表达率分别为 9.3%、1.8%、1.2%、0.4%和 0%。在 NSCLC 中，男性、T3 和 T4 期、中-低分化、肿瘤≥2cm、Ki67≥15%、SOX-2 阴性表达、中叶病变和腺癌是影响 SMARCA2 阴性表达的相对危险因素。在肺腺癌中，高级核、腺泡和乳头状组织形态、实性和微乳头状以及 TTF-1 阴性表达是影响 SMARCA2 阴性表达的相对危险因素。Kaplan-Meier 生存分析显示，SMARCA2 阴性组的 OS 较短。多因素生存分析显示，SMARCA2 阴性表达是 NSCLC 预后不良的独立相关因素。
总之，SMARCA2 阴性表达是 NSCLC 不良预后的独立预测因子，可能是 NSCLC 治疗的潜在靶点。
